Since the delivery of our first ultra-widefield device in 2000, Optos has continued to gather clinical evidence about the importance of seeing the peripheral retina especially in patients with diabetes.  optomap is the only ultra-widefield retinal imaging technology that captures up to 200° of the retina in a single image.

• optomap is clinically validated and supported by over 550 completed and ongoing clinical studies.

• optomap results are equal to ETDRS in all categories.¹ 

• optomap imaging demonstrates that diabetic lesions that occur outside of the ETDRS 7 standard fields predict increased risk of diabetic retinopathy progression over a 4 year period. ²

• Ultra-widefield retinal evaluation provides information that is necessary to completely assess the risk of DR progression.³

^{1,2,3 - Data on file}